Methylphenidate | Noven | ||
1.1, 1.6, 2.2, 3.3 MG/HR;Film, Extended Release, Transdermal |
Less Than $1000 mn
|
||
Less Than 5
|
Less Than 5
|
||
Less Than 5
|
None | ||
Less Than 5
|
Less Than 5
|
||
Indicated for the treatment of Attention Deficit Hyperactivity Disorder | |||
Yes
|
Daytrana | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 |
---|---|---|---|---|---|
****** | *** ********* | *** ********* | *** ********* | ********* | ********* |
***** | ******* | ******* | *** ********* | *** | *** |
Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
---|---|---|---|---|---|
****** | *** \ ** | ***** **, **** | ********* | **** | *** ****** ***** **** |
***** | **\ ** | ***** **, **** | ******* | ******** | ******** ** *** **, **** |